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Abstract
Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact
on a patient’s life, especially when the disease is moderate to severe. There is evidence that
treatment of psoriasis during the first years is conservative and frequently based on topical
agents which rarely clear lesions. Treatment with systemic agents including biologics is often
undertaken only when topical agents have proved unsuitable, even in patients with moderate
to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and
Crohn’s disease), targeted systemic treatment given early in the treatment pathway may
improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic
approach, undertaken early in the psoriasis treatment pathway (‘‘early intervention’’) with the
goal of complete clearance, may improve control of cutaneous symptoms and may also modify
disease course and burden. Critical points to address when designing an early intervention
study would include: the definition of psoriasis disease activity; patient selection; intervention
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Introduction
Psoriasis is a common condition, with a prevalence of 2% in the
USA and between 1.6% and 4.8% in Europe (1,2). It is associated
with significant impact on all aspects of patients’ lives (3). In some
patients, the cumulative effect of this impact perpetuates social
disconnection and stigmatization (4). Patients with severe psoriasis
have been shown to have a greater probability of low income and a
lower probability of working as a result of their condition,
compared to those with mild disease (5). The disease has also been
associated with significant reductions in health-related quality of
life (HRQoL), particularly in patients with severe disease and in
younger patients (6,7). The social impact of psoriasis has been
linked to changes in cognitive processing of facial expressions of
disgust encountered by psoriasis patients (8). Psoriasis has also
been reported to be associated with metabolic disorders including
obesity, non-alcoholic fatty liver disease (NAFLD), dyslipidaemia,
and diabetes, as well as disorders that confer an unfavorable
cardiovascular risk profile and higher mortality rates. These risks
may be directly related to disease severity and duration, although
the strength of the association varies across studies (9–11).
Psoriasis is an immune-mediated inflammatory disease (IMID)
affecting the skin which is associated with psoriatic arthritis in
about one-third of patients (12,13). Other IMIDs include ankylos-
ing spondylitis (AS), rheumatoid arthritis (RA), and Crohn’s
disease (CD). The distinguishing feature of IMIDs is that their
underlying pathology is caused by the dysfunction of the immune
system, resulting in chronic and damaging inflammation. As such,
the treatment of IMIDs overlaps, specifically in the management of
severe disease. A developing body of data suggests that more
aggressive therapeutic intervention earlier in the treatment pathway
in RA and CD may provide high levels of efficacy and tolerability,
with improved long-term patient outcomes and disease prognosis
(14–26). No such early intervention studies have been carried out in
psoriasis to date, although the possibility of modifying the course of
the disease has been proposed (27,28). In contrast, there is evidence
of a delay in using systemic agents and biologics in moderate-to-
severe psoriasis which exceeds 3 years in 50% of patients (29).
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The pathophysiology of psoriasis
There is a strong genetic basis for psoriasis which has
features in common with other IMIDs
Studies of psoriasis prevalence in families and concordance rates
in twins indicate a strong genetic component, which is in line with
other IMIDs. Farber and colleagues (30) first demonstrated this
with the finding that among 61 pairs of twins, the risk of psoriasis
was 2–3 times higher in monozygotic siblings, compared with
dizygotic siblings. At least, nine chromosomal loci with a
significant linkage to disease development have since been
identified and have been named psoriasis susceptibility
(PSORS) 1–9 (31).
Genome-wide scans have identified additional genes or gene
loci associated with psoriasis. Most of the genes so far identified
have to do with innate and adaptive immunity (32). These include
genes encoding the interleukin-23 receptor (IL23R), zinc-finger
protein 313 (ZNF313), CDKAL1, PTPN22, the IL-4–IL-13 gene
cluster and more recently, ERAP1 and late cornified envelope
(LCE) (33–60). The association of psoriasis with such genes has
raised a great deal of interest for two reasons. First, many of these
genes have a role in controlling and modifying the immune
response, which is the key driver of psoriasis and other IMIDs.
For example, the IL-12, IL-23, and IL-4–IL-13 gene cluster
products are associated with T-helper cell differentiation, cell-
mediated immune responses, and the development of some
autoimmune diseases (33,34,36). Second, many of the genes
associated with psoriasis overlap those associated with other
IMIDs. CDKAL1, for example, is a known risk factor for the
development of CD (35,59).
Subclinical inflammation in healed plaques following
treatment of psoriasis may trigger disease recurrence
Gene expression patterns in the involved skin of individuals with
psoriasis are significantly different from expression patterns in
uninvolved, clinically normal skin. Intriguingly, gene expression
studies in patients treated with etanercept suggest that resolution of
the epidermal reaction in psoriasis following successful systemic
treatment is not accompanied by full resolution of the inflamma-
tion, as defined by expression of key cytokines and chemokines
(61,62). This phenomenon of residual genomic expression has
been tentatively characterized as a ‘‘molecular scar’’, and may be
analogous to the non-reversible damage associated with progres-
sion of other IMIDs, such as RA. It may result in subclinical
inflammation responsible for early disease recurrence.
The observation that psoriasis is associated with polymorphism
in immunomodulating genes suggests that the basis of the disease
is a selective immune dysfunction. Hence, an effective treatment
strategy for psoriasis should target this dysfunction and should
take into account the genetic basis that persists despite clinically
effective therapy. In addition, because many of the genes
associated with psoriasis are also risk factors for other IMIDs,
systemic treatment approaches that are effective in one disease
may have a bearing on the clinical management of another.
Plaque development and the immune response in
psoriasis
The development of plaques of psoriasis is a multistage process
that involves overt activation of the innate and adaptive immune
systems (63–68). According to current concepts, the release of
endogenous DNA in combination with the anti-microbial protein
LL37 is detected by plasmacytoid dendritic cells (DCs), resulting
in the production of interferon-a (IFNa) (69,70). Recruitment of
plasmacytoid DCs in psoriatic skin is strictly dependent on the
chemerin/ChemR23 axis, and is temporally active during psoriatic
plaque development (71). Pro-chemerin is produced primarily not
only by dermal fibroblasts, but also by mast cells and endothelial
cells. Once secreted, it is activated by enzymes produced by
neutrophils, which extravasate in early psoriasis lesions. Other
cells of the innate immune system that respond include keratino-
cytes, which release IL-1b, IL-6, tumor necrosis factor-a (TNFa)
and various chemokines, and macrophages that secrete TNFa.
This induces recruitment and activation of myeloid DCs.
Myeloid DCs induce the antigen-specific activation and
differentiation of naı̈ve T-cells into type 17 or type 1 T-helper
cells (Th17 or Th1) by secreting IL-12 or IL-23, respectively.
These effector T-cells accumulate in the skin and promote plaque
formation through the release of a cocktail of pro-inflammatory
cytokines. Th17 cells secrete IL-17A, IL-17F, and IL-22, while
Th1 cells release TNFa and IFNg. These cytokines act directly on
keratinocytes resulting in hyperplasia and the production of
additional cytokines and chemokines (e.g. IL-1b, IL-6, TNFa,
CXCL8, and CCL20). The release of inflammatory mediators by
keratinocytes has several effects: the attraction of additional
immune cells (e.g. macrophages, and neutrophils), the production
of collagen and proteoglycans by fibroblasts, the activation and
perpetuation of an inflammatory response, and the propagation of
an adaptive immune response (11,65). Hence, the outcomes of
stimulation of a small region of psoriasis-predisposed skin results
in an immune reaction that can lead to the development of lesions
at local and distant body sites, as well as systemic effects.
The relationship between psoriasis and other IMIDs
Many of the loci associated with psoriasis are also associated with
other IMIDs. Furthermore, the pathophysiological basis of IMIDs
has, in recent years, been shown to involve the activation of an
inflammatory response and T-cells via DCs (72). It is, therefore,
unsurprising that patients with IMIDs frequently suffer from
related conditions. Psoriatic arthritis (PsA) – an erosive,
polyarticular, joint damaging disease that can progress to the
loss of function – occurs in 10–34% of individuals with psoriasis,
compared with a rate of 0.04–1.2% in unaffected individuals
(13,73,74). Prevalence of psoriasis has been shown to be
significantly higher in patients with inflammatory bowel disease
(CD or ulcerative colitis), compared with controls. Psoriasis
prevalence was also higher in first-degree relatives of these
patients (75). Finally, there appears to be an increased incidence
of PsA in patients with CD, and the latter disease shows an
association with a coding variant of the IL23R gene (76).
Although the localized inflammatory response leads to the
defining symptoms of IMIDs (skin lesions in psoriasis, inflam-
mation of the gastrointestinal tract in CD, and inflammation of the
joints in RA), activation of the adaptive immune system is not so
organ-specific. Indeed, the observation that patients with psoriasis
are more likely to suffer from another IMID suggests that
psoriasis is a systemic inflammatory disease, or has systemic
inflammatory consequences (72).
Research has since focused on the comorbidities associated
with psoriasis. Patients with severe psoriasis may have a higher
risk of developing ischemic heart disease, cerebrovascular
disease, peripheral vascular disease, and NAFLD compared with
controls (77–85). Patients with psoriasis are also more likely to
have risk factors for vascular disease (e.g. diabetes mellitus,
hypertension, and dyslipidaemia) than unaffected individuals,
although the results of epidemiological studies are heterogeneous.
There is a significant association between psoriasis and metabolic
syndrome (1,9), a strong predictor of diabetes and cardiovascular
disease, although the strength of the association varies across
studies (10,85,86). Psoriasis is associated with an increased risk
of cardiovascular disease (myocardial infarction and stroke) and
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mortality. However, there is still controversy about the specific
contributing role of cardiovascular risk factors, including hyper-
tension, smoking and hypercholesterolemia, versus the specific
role of psoriasis-related inflammation (13). It is still uncertain
whether psoriasis per se is an independent cardiovascular risk
factor (86,87). The recent finding that patients with psoriasis
show an overexpression in lesional skin of mRNA from genes
linked to cardiovascular risk (e.g. inflammatory mediators and
renin), corresponding to increased levels of the relevant proteins
in the serum, is highly suggestive in this regard (88).
Early intervention: towards a new treatment paradigm
for psoriasis
Psoriasis affects both physical and psychological aspects of a
patient’s life culminating in self-perpetuating social disconnection
(4,89). A cardinal aim of treatment in psoriasis is to ameliorate
the course of the disease, to prevent relapses, and to improve
overall prognosis by reducing severity. Unfortunately epidemio-
logical studies indicate that most physicians still use a conserva-
tive approach in psoriasis treatment. This results in long delay for
patients to achieve a high level of clearance. A more aggressive
approach with systemic agents or biologicals used earlier in the
treatment paradigm with the goal of complete clearance may
change the natural history of the disease, help more patients to
achieve long-term remission, and improve long-term outcomes
(26,27). One initiative to be explored further is the concept of
multidimensional patient education, which was shown to improve
patient outcome in a single-centre study (90).
This hypothesis has parallels in other clinical disciplines.
A clinical study in which patients with RA were treated with the
anti-TNF infliximab, found a markedly reduced risk of myocardial
infarction as early as at 6 months in responding patients, with
improvements in endothelial function after treatment (91,92).
In psoriasis, it remains to be determined whether the higher risk
of cardiovascular disease is related to systemic inflammation,
to traditional risk factors such as smoking, obesity and a sedentary
lifestyle, or to genetic factors (82,83). Nevertheless, early and
long-term control of psoriasis inflammation alongside appropriate
management of cardiovascular risk factors may help to improve
patient outcomes. Since the burden of psoriasis and the relative
risk for myocardial infarction appear to be much higher in
younger patients (78), patients with early-onset, moderate-
to-severe psoriasis may be the population most likely to benefit
from early intervention. The choice of the most suitable
therapeutic agents to initiate early intervention treatment requires
careful discussion (93).
Even though in most cases the clinical activity of psoriasis
does not lead to irreversible or progressive structural skin
damage, functional impairment can be very significant. The
overall impact on a patient’s life is related to the severity and
duration of active disease, taking into account not only the extent
but also the visibility of the lesions, the functional impairment
associated with palmoplantar, genital or nail disease, the presence
of associated arthritis, the frequency of relapses, and the need
for systemic treatment. These considerations suggest that a new
treatment paradigm may be required for psoriasis, especially for
young patients with severe disease who may carry a high risk of
stigmatization and social exclusion.
Early intervention in psoriasis: lessons from other IMIDs
Crohn’s disease
The clinical course of CD has some features in common with the
course of psoriasis. It is a disease characterized by unpredictable
phases of activity and quiescence. In CD, chronic inflammation
can lead to the development of complications (such as strictures,
fistulae, and abscesses) and definitive tissue damage. A minority
of CD patients present uncomplicated courses in which phases of
activity alternate with phases of complete remission. In most
patients, chronic inflammation can induce definitive damage even
in phases of symptomatic remission (94). However, there is an
increased early usage of immunosuppressants and anti-TNF
agents (95).
Anti-TNF therapies, with or without immunosuppressants,
have been demonstrated to alter the course of disease. Notably,
anti-TNFs can induce mucosal healing and reduce CD-related
hospitalizations and surgeries (96–98). Achievement of mucosal
healing is associated with a reduced rate of relapses (99). In
clinical practice, the agents are often used late in the disease
course, frequently in patients who have already developed
definitive tissue damage. The use of anti-TNF treatments early
in the course of CD has shown a high efficacy in the induction of
steroid-free clinical remission and endoscopic remission defined
as complete mucosal healing in patients with poor prognosis
(Table 1) (22,23,99). The challenge is now to identify predictors
of poor outcome, which would allow early, aggressive interven-
tion in subgroups of patients with poor prognosis.
Rheumatoid arthritis
The treatment of RA has changed significantly over the past
decade. This is a result of studies demonstrating that early,
aggressive therapy can achieve rapid disease control and may
prevent long-term radiographic progression and irreversible joint
damage. Treatment strategy trials have demonstrated that in the
majority of patients with RA, the following approach is the most
beneficial: goal-driven, dynamic treatment towards tight control
of disease activity, including early introduction of one or more
effective disease-modifying antirheumatic drugs (DMARDs) in
combination with prednisone or anti-TNF, which includes
tapering of the medication if remission or low disease activity
is achieved (100). Currently, patients with RA tend to be treated
first-line with a DMARD such as methotrexate (MTX) (15,16).
Biologics are licensed for patients who show inadequate response
or intolerance to DMARDs, and also for patients with severe,
active, and progressive RA not previously treated with DMARDs
(15). Studies have shown that the early use of biologics in
combination with MTX increases rates of remission, improves
symptoms and halts joint damage (Table 2) (14–22,101). In the
BeST study, after an earlier improvement in functional ability and
quality of life with initial combination therapy, clinical outcomes
were comparable across the groups from 1 year onwards and
stable up to 5 years. The initial combination groups showed less
joint damage in year 1. In years 2–5, annual progression was
comparable across the groups. After 5 years, initial combination
therapy resulted in significantly less joint damage progression,
reflecting the earlier clinical response (102). Patients treated with
MTX alone, even when achieving remission, will demonstrate
progression of damage predicted by subclinical synovitis (103).
Long-term data of early remission induction are now available
showing long-term benefits (104). For patients with RA, clinical
features are insufficient to give an accurate picture of the disease
state (105), and joint damage has been shown to progress despite a
sustained clinical remission in early rheumatoid arthritis patients
after etanercept interruption (106). A similar approach has been
undertaken in AS with patients in the prodromal period being
treated with infliximab, with evidence of early response and some
long-term benefit (107). This parallels the situation in psoriasis
where there seems to be a need to ‘‘reset’’ the disease, as shown at
various levels.
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Early intervention in psoriasis: crucial scientific
questions
Designing the candidate patient population
The candidate patient population for an early intervention trial in
psoriasis should have rapidly progressing, aggressive skin disease.
Natural history of psoriasis
There are only limited data available on the natural history of
psoriasis and on the factors predicting its prognosis. Although its
course is continuous in the majority of patients with severe
disease, psoriasis may show spontaneous exacerbations, improve-
ments, and sometimes, persistent remission. The time interval
between psoriasis episodes may vary from weeks to years. Studies
have distinguished early onset psoriasis, defined as occurrence
before the age of 40 years, and late onset psoriasis, occurring for
the first time after age 40 years; patients with early onset psoriasis
are more likely to have first-degree relatives affected, to express
susceptibility alleles at the HLA locus, and to experience severe
and recurrent disease (108,109). However, the potential link
between disease course and age of onset has not been confirmed
by other studies (110,111). No formal studies of the natural
history of psoriasis are available. A questionnaire survey to more
than 5000 patients in the USA found that psoriasis occurred in
males and females with nearly equal frequency. The mean age at
onset was 27.8 years with about 10% of patients having a disease
onset before the age of 10 years, 35% before the age of 20, and
58% before the age of 30. About one-third of the patients
indicated that one or more members of their families had
psoriasis. About 40% of patients stated that psoriasis had
disappeared completely with the duration of remission ranging
from 1 to 54 years (112). A study on more than 700 patients from
Sweden reported that in a period of 21 years, 71% of patients had
persistent lesions, 16% had intermittent lesions, and 13% were
disease free (113). In another study, persistent disease remission
was observed in 17% of patients after 5 years, in 14% after
10 years and in 6% after 20 years (114). Complete clearance
without treatment during some part of the year was reported by
about one-third of patients in a study conducted in the Indian
subcontinent (115). In most studies, sunlight exposure, summer,
or a warm temperate climate are associated with disease
improvement. Factors exacerbating psoriasis include stressful
life events, alcohol consumption, exposure to some drugs (e.g.
lithium salts and interferons), and obesity.
Treatment strategy and aims
The aim of an early intervention study in psoriasis is proposed as
follows: to obtain early, total or almost total clearance of psoriasis,
with modification of the natural disease course and reduction of
stigmatization.
The efficacy outcomes in an early intervention study may
include the long-term remission of cutaneous signs (from a
physician and patient perspective), improvements in HRQoL, and
evaluation of systemic inflammation. Disease activity in psoriasis
is typically measured using Psoriasis Area and Severity Index
(PASI) responses. The PASI response appropriate for an early
intervention study (up to and including PASI 100, or total
clearance) needs to be defined. In most clinical studies, the
outcome parameters have been PASI 75 (75% reduction in PASI
score versus baseline) and a subjective improvement in quality of
life. On one hand, these goals are assessed in the short term,
within 10–16 weeks of treatment initiation, corresponding to the
induction phase of treatment. A PASI 50 response and a reduction
from baseline in DLQI score of at least five have been proposed as
minimum efficacy goals in daily practice, although PASI 50 may
be considered insufficient by many patients (93,97). On the other
hand, therapeutic goals in the maintenance phase of treatment
should be defined in terms of complete or nearly complete
blanching, or minimal disease activity, regardless of baseline
values. Thus, a static Physician’s Global Assessment (PGA) of 0
or 1, or an absolute PASI score55, might be more suitable than a
PASI 75 response (116), with the patient’s HRQoL no longer be
affected by the disease (e.g. a Dermatology Life Quality Index
[DLQI] score of 0 or 1).
In order to be able to alter the natural history of psoriasis by
early intervention, a better understanding of the pathophysiology
and natural course of the condition is required. This will enable
more disease-specific intervention and treatment to be initiated
earlier in the course of the condition. For example, it is not
currently clear if systemic inflammation results from a spillover
of inflammatory mediators from skin into the circulation, or just
coincides with psoriasis due to an increased disposition for
immune-mediated inflammation in general. If one assumes that
inflammatory processes are continuing even in the absence of skin
lesions, it may be difficult to classify the disease as in remission
or inactive. In order to accurately quantify psoriasis disease
activity and its relationship with systemic inflammation and
immune activation, biological markers must be identified. Studies
investigating biomarkers in PsA have identified C-reactive protein
Table 1. Summary of key studies assessing early intervention with biologics in Crohn’s disease (CD).
Treatment Patients Key outcomes
D’Haens (23) Step-up: corticosteroids then
AZA plus IFX (n¼ 66)
Top-down: AZA plus IFX (n¼ 67)
133 corticosteroid-naı̈ve CD
patients
Corticosteroid-free remission at week 52 in
61.5% of top-down and 42.2% of step-up
patients (95% CI 2.4–36.3, p¼ 0.278)
Top-down treatment led to more rapid reductions
in CRP at week 10 than step-up (15.0 mg/l
versus 4.2 mg/l, respectively; p¼ 0.0244)
Colombel (24) AZA plus placebo (n¼ 170)
IFX plus placebo (n¼ 169)
AZA plus IFX (n¼ 169)
508 patients with moderate-to-
severe CD naı̈ve of immuno-
suppressive or biologic therapy
Corticosteroid-free clinical remission at week 26
in 31% with AZA plus placebo, 44% with IFX
plus placebo (p¼ 0.009 versus AZA plus
placebo), and in 57% with IFX plus AZA
(p50.001 versus AZA plus placebo,
p¼ 0.022 versus IFX plus placebo)
Higher CRP levels at baseline were associated
with the achievement of remission during
treatment with AZA plus IFX
6-MP, 6-mercaptopurine; AZA, azathioprine; CRP, C-reactive protein; IFX, infliximab.
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(CRP) and matrix metalloproteinase-3 (MMP-3) as promising
candidate markers (117). Similarly, rates of corticosteroid-free
clinical remission in CD patients receiving infliximab were
greater among subgroups of patients with baseline CRP levels
0.8 mg/dl (24).
A second question in the design of an early intervention study
is exactly how ‘‘early intervention’’ is to be defined. In RA, a
qualitatively different effect with regard to joint damage has been
observed if an intervention is used at one timepoint compared
with another – the so-called ‘‘window of opportunity’’. In patients
with RA, one manifestation of this is the ability to stop treatment
without a disease flare. Clinical data have shown that flare is less
likely if RA patients are treated early with an anti-TNF plus
methotrexate, and if treatment takes place earlier after the
development of symptoms (i.e., a median of 5.5 months) (101).
It is, however, unclear if the timing of treatment similarly
influences effects and outcomes in psoriasis.
Based on data obtained in studies of other IMIDs, there are
three treatment paradigms that could be used in a psoriasis early
intervention study: (1) patients are moved more rapidly along the
existing treatment pathway, so systemic agents are used earlier;
(2) patients with severe aggressive disease enter a disease
management program including patient education, use of a
systemic or a biologic agent with the goal to obtain complete or
almost complete clearance; and (3) patients are treated with a
biologic or systemic therapy at the first presentation of psoriasis
and upon achieving remission are maintained on any conventional
systemic therapy for the long term to maintain remission.
Patient selection
Patient selection protocols will be largely dependent on the
definition of ‘‘early intervention’’. Early intervention could define
a time window for the onset of systemic or biologic therapy of 6–
12–24 months after first disease manifestation. However, patient
selection implies a spectrum of choices and outcomes. For
example, RA studies have shown that patients with early disease
(52 years) exhibit better treatment responses than those with late
disease (16). It is currently unclear if this would also apply in
psoriasis, although it can be hypothesized that biologic or
systemic treatment of psoriasis at disease onset might impact
the inflammatory cascade and favorably affect the long-term
course of psoriasis, and also halt social disconnection and
stigmatization. This could potentially be determined at diagnosis
using gene scans to identify those patients with high risk for
developing severe psoriasis, PsA, and/or other IMIDs according to
the presence of associated genes or single nucleotide polymorph-
isms (SNPs) at associated gene loci.
The clinical presentation of psoriasis (e.g. inflammatory
psoriasis and widespread disease) could also guide the decision.
For example, it has been shown that in patients with psoriasis the
area of disease involvement during stable disease correlates with
nail and joint involvement and the need for a second-line therapy
(118). Plaque thickness has also been found to correlate with
treatment response, where patients with thin plaques were more
likely to report a complete clinical response following treatment
with topical corticosteroids and phototherapy, but not systemic
therapy (119).
Finally, there is the question of whether any types of psoriasis
should be excluded from early intervention. Of course, only
patients with moderate-to-severe psoriasis are eligible for treat-
ment with systemic agents or biologics, making mild psoriasis
(limited disease) patients ineligible for study. However, few
patients develop severe psoriasis at or near disease onset. Despite
this, a true early intervention approach requires treatment as
rapidly as possible following the first identification of symptoms.
In an ongoing early intervention study in psoriatic arthritis, the
maximum period between first symptoms of psoriatic arthritis and
enrolment was defined as 2 years (27,120).
In addition, there are several other forms of psoriasis that affect
the HRQoL of patients to a similar degree. Although most
research has been carried out on individuals with plaque-type
psoriasis, other forms such as guttate, nail, or scalp psoriasis are
equally as distressing and may be more or less responsive to
treatment than plaque psoriasis.
Endpoint selection
Remission, or duration of off-treatment response, has been
inconsistently defined in clinical studies of psoriasis therapies,
and occasionally not defined at all. Definitions have included time
until recurrence of 50% of baseline psoriasis, time until
recurrence of 3% or more body surface area of psoriasis when
the patient was ‘‘clear’’, and time until first worsening of existing
lesions or appearance of a new lesion (121). A recent consensus
publication has suggested the following definition for treatment
success during the maintenance phase of treatment (i.e., the
treatment period after the induction phase): ‘‘an improvement of
PASI of 75% (DPASI 75%) as compared with disease severity
at the time of treatment initiation’’ (122). According to another
consensus, satisfactory therapeutic control of psoriasis should be
defined in absolute, rather than relative terms: sustained complete
or almost complete clearance (PGA 1) or the minimal degree of
involvement that can be controlled with topical treatment (PGA
2, PASI55) (116). Similarly, the definition of loss of adequate
response, treatment failure, or relapse are variable between
studies. Indeed, the REVEAL study, which compared the efficacy
of adalimumab versus placebo, defined relapse as ‘‘5PASI 50
relative to baseline with 6-point increase in PASI from week
33’’ (123). Other definitions, such as a PGA score42, should also
be considered.
In CD, the present therapeutic guidelines follow a sequential
step-up approach that focuses on treating acute disease or
‘‘inducing clinical remission’’ and subsequently aims to ‘‘main-
tain clinical response’’ (124). In this regard, a common definition
for psoriasis remission should be agreed among dermatologists.
One possible definition could be the dermatologic element of the
MDA (minimal disease activity) definition for psoriatic arthritis
(PASI 1 and BSA 3%) (125).
Assessing the benefits of early intervention
The aim of early intervention would be to improve the long-term
course and prognosis of psoriasis. Currently, there are no
predictors that would define the future course and severity of
psoriasis at disease onset in the individual patient. Post-hoc
subanalyses of clinical trials might provide some clues regarding a
possible correlation between early treatment (shorter duration of
(severe) disease and longer relapse times after adjusting for
baseline PASI, arthritis, CRP, body weight, age, sex, and biologic
used. Outcome measures or endpoints could include disease
severity over time; HRQoL over time; duration of disease-free
remissions after treatment breaks; treatment response after change
to conventional therapy; laboratory indicators of systemic
inflammation; retreatment or change to conventional therapy;
and biomarkers or surrogate indicators of systemic inflammation.
Early pilot studies have suggested that the treatment of psoriasis
with systemic agents or anti-TNFs may improve biomarkers of
cardiovascular risks (126,127). Demonstration of a reduction in
the incidence of cardiovascular or cerebrovascular events, meta-
bolic syndrome, or PsA would represent a secondary gain, but the
ultimate goal from a dermatological perspective, taking into
account that no structural irreversible damage occurs in the skin,
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should be prolonged medication-free remission. The added value
of early intervention may be difficult to define. It may require the
comparison of large age-, sex-, and ethnically matched patient
populations adjusted for additional risk factors such as smoking,
body-mass index, waist circumference, hypertension, dyslipidae-
mia or diabetes, and the corresponding therapeutic interventions.
Although the measures listed above provide evidence of the
presence or absence of clinical disease, subclinical activity must
also be considered. In RA, one study showed that when assessed
using power Doppler and MRI, 19% of patients thought to be in
remission displayed deterioration in radiographic damage (105).
Likewise, the inflammatory and epithelial genes that are
associated with residual disease genomic profile – or genetic
memory – in psoriasis may provide an estimation of subclinical
disease activity and probability of relapse with or without
treatment; while plaque thickness may provide a good measure
of treatment response and the likelihood of a patient responding to
treatment (62,119).
Carefully designed study protocols are required to document
the benefits of early intervention in psoriasis. (For example,
achieving maintained complete remission or MDA for a given
period of time might provide a rationale for biologic treatment
discontinuation (128) if this reduces the likelihood of relapse
requiring systemic treatment.) It should also be considered that
the required observation periods for such studies in psoriasis
might exceed those that can be covered by clinical trials and, as
such, necessitate the transfer of patients from early intervention
studies into long-term observational pharmacovigilance registries,
e.g. BADBIR in the UK, Psocare in Italy, and PsoBest in
Germany. Indeed, these registries may themselves provide data on
the effect of intervention on the course of disease.
Conclusions
Psoriasis is an inflammatory disease that not only affects the
skin but may also act systemically to influence serious
comorbidities. Many agents currently used early in treating
psoriasis target the development of skin lesions. However,
disease control and long-term outcomes of psoriasis as a
systemic disease are key treatment goals in psoriasis. The
efficacy of early intervention has been demonstrated in many
studies of patients with RA and CD. However, there is a need to
reach consensus on a number of definitions before such studies
could be carried out in psoriasis. It is important to accumulate
more data on the natural history of psoriasis, to have in place a
universally accepted definition of disease activity in psoriasis
and to have identified biomarkers to quantify changes in disease
activity and subclinical inflammation during and after treatment.
An early intervention study must also identify the most
appropriate way of using early intervention, the patients that
should be enrolled in the study, and the treatments that should
be included. Resolving these issues and initiating early inter-
vention studies in psoriasis is essential to identify new treatment
paradigms with the potential to change the course of the disease
and improve patient outcomes in the long term.
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